Literature DB >> 105739

Long-term chrysotherapy in rheumatoid arthritis.

R Srinivasan, B L Miller, H E Paulus.   

Abstract

The efficacy of chrysotherapy appears to increase with prolonged administration. In patients who were followed for 3 years after gold therapy was started, remissions occurred in 73% of those who continued chrysotherapy. Only 6% of those who stopped gold injections during the first 18 months subsequently developed "spontaneous" remissions, although initially both groups had comparable moderately severe rheumatoid arthritis of 6 to 8 years' duration. Therefore, in the absence of definite toxicity, maintenance gold injections should be continued indefinitely.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 105739     DOI: 10.1002/art.1780220201

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  12 in total

1.  Prospective six year follow up of patients withdrawn from a randomised study comparing parenteral gold salt and methotrexate.

Authors:  O Sander; G Herborn; E Bock; R Rau
Journal:  Ann Rheum Dis       Date:  1999-05       Impact factor: 19.103

2.  A 10 year follow up of parenteral gold therapy in patients with rheumatoid arthritis.

Authors:  G Bendix; A Bjelle
Journal:  Ann Rheum Dis       Date:  1996-03       Impact factor: 19.103

3.  Disease-modifying drugs for rheumatoid arthritis. Asset or liability?

Authors:  H A Bird
Journal:  Clin Rheumatol       Date:  1987-12       Impact factor: 2.980

4.  Therapeutic workshop on modifying the disease process in rheumatoid arthritis: immunosuppression in perspective.

Authors: 
Journal:  Ann Rheum Dis       Date:  1982       Impact factor: 19.103

Review 5.  Gold-based therapy: From past to present.

Authors:  Alice Balfourier; Jelena Kolosnjaj-Tabi; Nathalie Luciani; Florent Carn; Florence Gazeau
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-08       Impact factor: 11.205

Review 6.  Rational use of disease-modifying antirheumatic drugs.

Authors:  D E Furst
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

Review 7.  A clinical and economic review of disease-modifying antirheumatic drugs.

Authors:  S E Gabriel; D Coyle; L W Moreland
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

8.  Does second-line therapy affect the radiological progression of rheumatoid arthritis?

Authors:  T Pullar; J A Hunter; H A Capell
Journal:  Ann Rheum Dis       Date:  1984-02       Impact factor: 19.103

9.  Auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. Cooperative systematic studies of rheumatic diseases.

Authors:  H J Williams; J R Ward; M J Egger; J C Reading; C O Samuelson; M Altz-Smith; R W Willkens; M A Solsky; S P Hayes; D Furst
Journal:  Clin Rheumatol       Date:  1984-03       Impact factor: 2.980

10.  Second line therapy in rheumatoid arthritis--a four year prospective study.

Authors:  T Pullar; J A Hunter; H A Capell
Journal:  Clin Rheumatol       Date:  1985-06       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.